Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells 17,795 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 17,795 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $18.55, for a total value of $330,097.25. Following the sale, the chief financial officer directly owned 145,355 shares in the company, valued at approximately $2,696,335.25. This trade represents a 10.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Ivan Hyep also recently made the following trade(s):

• On Friday, November 21st, Ivan Hyep sold 605 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.15, for a total value of $10,980.75.
• On Thursday, October 9th, Ivan Hyep sold 6,415 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.23, for a total value of $116,945.45.
• On Tuesday, October 7th, Ivan Hyep sold 18,244 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.22, for a total value of $332,405.68.
• On Wednesday, October 8th, Ivan Hyep sold 5,627 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.21, for a total value of $102,467.67.
• On Monday, October 6th, Ivan Hyep sold 6,514 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.17, for a total value of $118,359.38.

Bicara Therapeutics Price Performance

Shares of NASDAQ BCAX traded down $0.42 during midday trading on Tuesday, reaching $18.46. 1,136,579 shares of the company traded hands, compared to its average volume of 608,772. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -8.24 and a beta of -0.76. The stock has a 50-day moving average price of $15.45 and a 200 day moving average price of $12.65. Bicara Therapeutics Inc. has a 52 week low of $7.80 and a 52 week high of $22.67.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Monday, November 10th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.12). As a group, analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Institutional Investors Weigh In On Bicara Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp increased its holdings in shares of Bicara Therapeutics by 4.8% in the 1st quarter. Bank of New York Mellon Corp now owns 42,192 shares of the company’s stock valued at $550,000 after purchasing an additional 1,924 shares during the period. New York State Common Retirement Fund purchased a new position in Bicara Therapeutics during the first quarter valued at approximately $52,000. CWM LLC acquired a new position in Bicara Therapeutics in the 1st quarter valued at approximately $29,000. Victory Capital Management Inc. purchased a new stake in Bicara Therapeutics in the 1st quarter worth approximately $449,000. Finally, TD Asset Management Inc boosted its stake in shares of Bicara Therapeutics by 27.8% during the 1st quarter. TD Asset Management Inc now owns 130,938 shares of the company’s stock valued at $1,706,000 after buying an additional 28,518 shares during the period.

Analyst Ratings Changes

Several analysts have recently weighed in on BCAX shares. Wedbush restated an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a report on Monday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Tuesday, October 14th. Wells Fargo & Company upped their price target on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Piper Sandler began coverage on shares of Bicara Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $36.00 price objective for the company. Finally, HC Wainwright lowered their price objective on shares of Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, August 22nd. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $29.67.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.